文献速递湿疹皮炎与荨麻疹

外用糖皮质激素可正常化婴儿特应性皮炎的皮肤和全身炎症标志物

Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis.
PubMed 文献 · Br J Dermatol · 2021-03-07

治疗改善了疾病严重度,皮肤和血浆免疫标志物较基线显著变化,但多数未达健康对照水平;经皮水分丢失下降,天然保湿因子无显著变化。提示皮肤是婴儿AD全身细胞因子紊乱的重要来源。

要点

  • 6周外用糖皮质激素可显著改善婴儿AD疾病严重度。
  • 皮肤与血浆免疫标志物较基线显著变化,但多数未恢复至健康水平。
  • 皮肤IL-18、IL-8、IL-1α及CCL17、CCL22变化最突出。

核心结论

  • 外用治疗对全身生物标志物的显著影响提示皮肤是婴儿AD全身细胞因子紊乱的主要来源。
  • 通过外用治疗纠正全身免疫紊乱可能带来长期获益。

研究设计与样本

  • 检测角质层和血浆生物标志物及角质层天然保湿因子,治疗前后比较。
  • 免疫标志物涵盖固有免疫、Th1和Th2免疫、血管生成及血管因子。
  • 疾病严重度用SCORAD评估,皮肤屏障功能用经皮水分丢失评估。

主要发现

  • 外用糖皮质激素治疗可预期地改善疾病严重度。
  • 皮肤和血浆免疫标志物水平较基线显著变化,但多数未达健康对照水平。
  • 角质层变化最突出的是固有免疫激活标志物IL-18、IL-8、IL-1α及Th2趋化因子CCL17、CCL22。
  • 血液中变化最大的是Th2偏倚标志物CCL17、IL-13、CCL22、IL-5和CCL26。
  • 治疗后经皮水分丢失下降,天然保湿因子较基线无显著变化。

临床怎么用

  • 婴儿AD外用糖皮质激素治疗不仅改善皮肤,也可调节全身炎症标志物。
  • 临床评估可关注皮肤和全身炎症标志物变化,但多数指标未必恢复正常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is the most common inflammatory skin disease. It is highly heterogeneous in clinical presentation, treatment response, disease trajectory and associated atopic comorbidities. Immune biomarkers are dysregulated in skin and peripheral blood. AIMS: We used noninvasive skin and peripheral biomarkers to observe the effects of real-world topical corticosteroid (TCS) treatment in infants with AD, by measuring skin and blood biomarkers before and after therapy. METHODS: Seventy-four treatment-naïve infants with AD underwent 6 weeks of TCS treatment. Stratum corneum (SC) and plasma blood biomarkers as well as SC natural moisturizing factor (NMF) were measured before and after TCS therapy. Immune markers included innate, T helper (Th)1 and Th2 immunity, angiogenesis, and vascular factors. AD severity was assessed by the Scoring Atopic Dermatitis index, and skin barrier function by transepidermal water loss (TEWL). Twenty healthy infants were recruited as controls. RESULTS: TCS therapy predictably led to improvement in disease severity. Levels of immune markers in the skin and in the peripheral blood showed significant change from baseline, though most did not reach healthy control levels. The most prominent change from baseline in the SC was in markers of innate immune activation, interleukin (IL)-18, IL-8 and IL-1α, and the Th2 chemokines C-C motif chemokine (CCL)17 and CCL22. In blood, the largest changes were in Th2-skewed biomarkers: CCL17, IL-13, CCL22, IL-5, and CCL26. TEWL decreased after therapy; no significant changes from baseline were found for NMF. CONCLUSIONS: The profound impact of topical therapy on systemic biomarkers suggests that the skin compartment generates a major component of dysregulated systemic cytokines in infant AD. There may be long-term beneficial effects of correcting systemic immune dysregulation through topical therapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. McAleer MA, Jakasa I, Stefanovic N, et al. Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis. Br J Dermatol. 2021. PMID: 33269467. doi:10.1111/bjd.19703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。